Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 14/20 | 0.64 |
| ▸ | MMP13 | P45452 | 10/20 | 0.64 |
| ▸ | MMP3 | P08254 | 8/20 | 0.64 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.52 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.52 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.52 |
| ▸ | MMP9 | P14780 | 7/20 | 0.51 |
| ▸ | MMP1 | P03956 | 4/20 | 0.51 |
| ▸ | MMP7 | P09237 | 1/20 | 0.51 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4333373 | 1.00 | MMP2 (0.64) | MMP2MMP13MMP3TDP1SLC1A3 | |
| SCHEMBL5001728 | 0.87 | MMP2 (0.50) | MMP2MMP13MMP3TDP1SLC1A3 | |
| SCHEMBL5001726 | 0.87 | MMP2 (0.50) | MMP2MMP13MMP3TDP1SLC1A3 | |
| SCHEMBL4347005 | 0.87 | MMP13 (0.60) | MMP2MMP13MMP3MMP9MMP1 | |
| SCHEMBL4346999 | 0.87 | MMP13 (0.60) | MMP2MMP13MMP3MMP9MMP1 | |
| SCHEMBL31630175 | 0.86 | MMP2 (0.49) | MMP2MMP13MMP3TDP1SLC1A3 | |
| SCHEMBL4342507 | 0.86 | MMP2 (0.59) | MMP2MMP13MMP3SLC1A3SLC1A2 | |
| SCHEMBL4342501 | 0.86 | MMP2 (0.59) | MMP2MMP13MMP3SLC1A3SLC1A2 | |
| SCHEMBL4564383 | 0.85 | MMP2 (0.67) | MMP2MMP13MMP3SLC1A3SLC1A2 | |
| SCHEMBL4564384 | 0.85 | MMP2 (0.67) | MMP2MMP13MMP3SLC1A3SLC1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009153569-A2 | CB1 RECEPTOR MODULATORS | 7TM PHARMA A/S (DK) | 2009-12-23 | — | — | WO | disclosed |
| US-7612060-B2 | Triazoles and methods of use | AMGEN INC. (US) | 2009-11-03 | — | — | US | disclosed |
| US-20080249106-A1 | 3-(1-((R)-7-((4-fluoropiperidin-1-yl)methyl)-3,4-dihydro-2H-chromen-4-yl)-1H-1,2,3-triazol-4-yl)-2-(4-methylphenylsulfonamido)propanoic acid; chronic pain analgesics; side effect reduction | AMGEN INC. | 2008-10-09 | — | — | US | disclosed |
| US-7414134-B2 | B1 bradykinin receptor antagonists | AMGEN INC. (US) | 2008-08-19 | — | — | US | disclosed |
| US-20060100213-A1 | Triazoles and methods of use | AMGEN INC. (US) | 2006-05-11 | — | — | US | disclosed |
| US-20060100216-A1 | Novel B1 bradykinin receptor antagonists | AMGEN INC. (US) | 2006-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100213-A1 | Triazoles and methods of use | CYP3A5, CYP3A43, CYP2E1 | MMP2 1903/4885MMP13 1034/4885MMP3 412/4885 |
| US-20080249106-A1 | 3-(1-((R)-7-((4-fluoropiperidin-1-yl)methyl)-3,4-dihydro-2H-chromen-4-yl)-1H-1,2,3-triazol-4-yl)-2-(4-methylphenylsulfonamido)propanoic acid; chronic pain analgesics; side effect reduction | BDKRB1, BDKRB2, FPR1 | MMP2 3179/4885MMP13 1535/4885MMP3 1906/4885 |
| US-20060100216-A1 | Novel B1 bradykinin receptor antagonists | BDKRB1, BDKRB2, EDNRB | MMP2 2323/4885MMP13 2357/4885MMP3 2905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.